A SPECIAL MEETING REVIEW EDITION: Highlights in Crohn’s Disease and Ulcerative Colitis: Digestive Disease Week 2012 May 19-22, 2012 • San Diego, California Special Reporting on: • Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active UC: PURSUIT-SC • The Future of IBD Therapy: Individualized and Optimized Therapy and Novel Mechanisms • Infliximab Concentration and Clinical Outcome in Patients with UC • Vedolizumab Induction Therapy for UC: Results of GEMINI I, A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase III Trial • Novel Infliximab and Antibody-to-lnfliximab Assays Are Predictive of Disease Activity in Patients with CD • Accelerated Step-Care Therapy with Early Azathioprine Versus Conventional Step-Care Therapy in CD • PIANO: A 1,000-Patient Prospective Registry of Pregnancy Outcomes in Women with IBD Exposed to Immunomodulators and Biologic Therapy PLUS Meeting Abstract Summaries With Expert Commentary by: William J. Sandborn, MD Chief of the Division of Gastroenterology Director of the UCSD IBD Center UC San Diego Health System La Jolla, California